Category: St. Jude MedicalSyndicate content

St. Jude lands FDA win for quadripolar pacing, warns docs on Riata leads

November 30, 2011 by MassDevice staff

St. Jude touts a regulatory win for the first quadripolar pacing system, while also warning doctors that its Riata defibrillator leads have a higher failure rate than previously estimated.

St. Jude logo

St. Jude Medical Inc. (NYSE:STJ) sported some good news and some bad news, touting a regulatory win for its novel quadripolar pacing system while also warning doctors that its Riata defibrillator leads may pose a greater risk than previously reported.

The St. Paul, Minn.-based med-tech titan announced FDA clearance for the Unify Quadra cardiac resynchronization therapy defibrillator and Quartet left ventricular quadripolar pacing lead, calling it an industry first.

St. Jude touts industry first with U.S. clearance of quadripolar pacing system

November 30, 2011 by MassDevice

Source: 
MarketWatch

ST. PAUL, Minn., Nov 29, 2011 (BUSINESS WIRE) -- St. Jude Medical, Inc. STJ +6.19% , a global medical device company, today announced it has received U.S. Food and Drug Administration (FDA) approval of its Unify Quadra(R) cardiac resynchronization therapy defibrillator (CRT-D) and Quartet(R) Left Ventricular Quadripolar Pacing Lead. The company will begin shipping the products to its sales force to begin providing to customers immediately.

MassDevice.com +7 | Shrinking stents, deep brain stimulation, ex-execs in federal prison, Covidien's $325M grab, JNJ's appeal for Sedasys, Rosch's disdain for ObamaCare and Medtronic's unloading of Physio-Control made headlines this week

November 26, 2011 by MassDevice staff

The top seven medical device stories for the week of November 21, 2011.

Plus 7 Thanksgiving logo

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.

MassDevice.com +3 | St. Jude's implant effective in study, Synthes execs get 9 months, Covidien nabs Barrx for $325 M

November 21, 2011 by MassDevice staff

The top three medical device stories for November 21, 2011.

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com's coverage highlights our three biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you're still in the know with MassDevice +3.

St. Jude's deep brain stimulator proves effective against severe depression

November 21, 2011 by MassDevice staff

Results from St. Jude's study of its Libra deep brain stimulator show reduced symptoms among patients suffering from highly treatment-resistant depression.

Glowing Neuron image

St. Jude Medical's (NYSE:STJ) deep brain stimulation implant proved safe and effective in treatment of patients with severe therapy-resistant depression.

Results from the first multi-center pilot study, conducted among 21 patients, found that 62 percent reported a 40 percent reduction in depression symptoms and 29 percent reported that their symptoms were cut in half after one year.

St. Jude Medical Study Results Confirm Benefit of Treating Patients Suffering from Severe Depression with Deep Brain Stimulation

November 21, 2011 by MassDevice

Source: 
St. Jude Medical

Results from the first multi-center pilot study of deep brain stimulation (DBS) for major depressive disorder were published online today by the Journal of Neurosurgery. The study, conducted at three research facilities in Canada, was designed to replicate and build upon an earlier study by Dr. Andres Lozano and Dr. Helen Mayberg which was published in the journal Neuron in 2005. Sponsored by St. Jude Medical, Inc. (NYSE:STJ), the study demonstrates significant improvement in depression symptoms among patients who are highly treatment resistant.

Zimmer's battles, St. Jude fighting Access Closure, patient tracking, Becton Dickinson's buyout potential, Stryker's massive layoffs, two decades of Olympus' loss concealment and Sapien's spiked clinical trial made headlines this week | MassDevice.com +7

November 12, 2011 by MassDevice staff

The top seven medical device stories for the week of November 17, 2011.

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp